November 8, 2011 – Boston Scientific reports clinical endpoint data from its PLATINUM Long Lesion trial, demonstrating excellent outcomes for the Promus Element everolimus-eluting platinum chromium (PtCr) stent system in patients with long coronary lesions. Results were presented today by Paul S. Teirstein, M.D., of the Scripps Clinic in La Jolla, Calif., and co-principal investigator of the trial, at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in San Francisco.
The PLATINUM Long Lesion trial compared the Promus Element stent system in patients with long de novo lesions (>24 to less than or equal to 34 mm in length and greater than or equal to 2.50 to less than or equal to 4.25 mm in diameter) to a pre-defined performance goal based on historical results in patients treated with the 32 mm Taxus Express2 paclitaxel-eluting stent system. The prospective, single-arm trial enrolled 102 patients at 30 sites.
"The Promus Element stent achieved impressive clinical outcomes in this patient population with long lesions," said Teirstein. "This everolimus-based stent, built on an advanced platinum chromium platform, demonstrated low rates of revascularization while reporting no cardiac death, myocardial infarction or stent thrombosis at one year, and should offer physicians greater confidence and flexibility in treating longer lesions with a single stent."
The PLATINUM Long Lesion study met its primary endpoint of target lesion failure (TLF) at 12 months with a 3.2 percent rate for the Promus Element stent in the per protocol population compared to a pre-specified performance goal of 19.4 percent (p<0.001) based on historical outcomes for the Taxus Express stent. Components of TLF in the per protocol population for the Promus Element stent included cardiac death related to the target vessel (0.0 percent), myocardial infarction (MI or heart attack) related to the target vessel (0.0 percent) and ischemia-driven target lesion revascularization (TLR, 3.2 percent). Clinical outcome rates at 12 months in the intent-to-treat population were low for all death (1.0 percent), cardiac death (0.0 percent), MI (0.0 percent), TLR (3.1 percent) and ARC definite/probable stent thrombosis (0.0 percent). Clinical procedural success was achieved in 100 percent of patients.
The Promus Element Stent System received CE Mark approval and was launched in Europe and other international markets in 2009. In February 2011, Boston Scientific launched the Promus Element stent system in India, and, in October, announced the commencement of a phased launch in China. The Promus Element stent features an innovative PtCr alloy and new stent design to offer greater radial strength, exceptional deliverability and high visibility. The thin-strut stent is designed for improved conformability, minimal recoil and uniform lesion coverage and drug distribution. The advanced low-profile delivery system, coupled with increased radiopacity, facilitates precise delivery of the stent across challenging lesions.
In the United States, the Promus Element sent is an investigational device, limited by federal law to investigational use only and not available for sale.
For more information: www.bostonscientific.com
November 18, 2024 
